Every 10-Q that SelectQuote, Inc. (SLQT) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow SLQT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SLQT filings page.
SelectQuote reported strong quarterly results with higher revenue and a sharp jump in profitability. For the three months ended December 31, 2025, revenue rose to $537.1 million from $481.1 million, driven largely by growth in its Healthcare Services pharmacy business, which increased to $227.2 million from $180.0 million.
Net income improved to $69.3 million versus $53.2 million a year earlier, helped by a $19.3 million favorable change in warrant fair value and lower interest expense. After paying and accruing $18.1 million of dividends and accretion on its Senior Non-Convertible Preferred Stock, net income attributable to common shareholders was $51.2 million.
For the first six months of the fiscal year, revenue reached $865.9 million, up from $773.3 million, and net income climbed to $38.8 million from $8.7 million. Operating cash flow remained negative at $(21.6) million, while total debt increased to $405.8 million and preferred stock carried a liquidation preference of $394.2 million.
SelectQuote, Inc. reported results for the quarter ended September 30, 2025. Total revenue was $328.8 million, up from $292.3 million, driven by Pharmacy revenue of $218.5 million versus $152.9 million. Commissions and other services were $110.3 million versus $139.4 million.
Loss from operations widened to $(40.7) million from $(12.0) million as costs rose with volume. Net interest expense improved to $(11.8) million from $(23.0) million. A $15.0 million non‑cash gain from change in fair value of warrants reduced overall loss, resulting in net loss of $(30.5) million, compared with $(44.5) million a year ago. After $17.5 million of accumulated dividends and accretion on Senior Non‑Convertible Preferred Stock, net loss attributable to common shareholders was $(47.9) million (basic and diluted EPS $(0.26)).
Cash, cash equivalents and restricted cash ended at $15.7 million. Operating cash flow was $(21.6) million. Debt totaled $393.1 million, including Term Loans of $310.4 million and a $15.0 million revolving balance; the company was in compliance with covenants. Shares outstanding were 175,946,798 as of September 30, 2025.